Call our 24 hours, seven days a week helpline at 800.272.3900

24/7 Helpline 800.272.3900

CMS Treatment Coverage Policy: What It Means for People Living with Alzheimer’s

CMS Treatment Coverage Policy: What It Means for People Living with Alzheimer’s
Share or Print this page
Share or Print this page

In April 2022, the Centers for Medicare & Medicaid Services (CMS) issued an unprecedented decision restricting Medicare coverage of Food and Drug Administration (FDA)-approved treatments that target amyloid for Alzheimer's disease. But following extensive efforts by the Alzheimer's Association, bipartisan members of Congress, state attorneys general, clinicians and, most importantly, advocates from communities all across the country, CMS has updated its coverage plan for traditionally approved FDA treatments.

Medicare now will cover FDA-approved monoclonal antibody treatments that receive traditional approval if clinicians participate and enter data in a simple registry. This policy applies to all currently FDA-approved monoclonal antibody treatments, including lecanemab (Leqembi®) and aducanumab (Aduhelm®), and others that may receive approval. (Aducanumab will be discontinued on Nov. 1, 2024. Please connect with your provider on treatment options.)

In addition, in October 2023, CMS issued a new policy that expands coverage of brain amyloid positron emission tomography (PET) imaging for the diagnosis of Alzheimer's disease. Access to amyloid PET imaging for Alzheimer's diagnosis is essential in the new era of treatments.

Your voice is important to the fight

By generously sharing your time and resources, you have brought us to this pivotal moment — but we must keep going. Learn about all of the ways people like you are moving the needle for the cause.

Get Involved

More information


Navigating Treatment Options

Promising new treatments can help people living with Alzheimer's. It is important to learn as much as you can about which drugs are available.


Our Commitment to Transparency

The Alzheimer’s Association received just over 1% of its total 2022 contributed revenue from the biotechnology, pharmaceutical, diagnostics and clinical research industry.


Mild Cognitive Impairment (MCI)

Learn about mild cognitive impairment, an early stage of memory loss or other cognitive ability loss (such as language or visual/spatial perception).

We're here for you

The Alzheimer’s Association 24/7 Helpline (800.272.3900) is available around the clock, 365 days a year. Through this free service, specialists and master’s-level clinicians offer confidential support and information to people living with dementia, caregivers, families and the public.

About the Alzheimer’s Association

The Alzheimer's Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®.

Keep Up With Alzheimer’s News and Events